Eli Lilly Buying Obesity Drugmaker Versanis In Near-$2B Deal
Kirkland & Ellis LLP-led pharmaceutical company Eli Lilly and Co. said Friday it has agreed to buy Versanis Bio, a clinical-stage biopharmaceutical company advised by Goodwin Procter LLP, for up to roughly $1.9...To view the full article, register now.
Already a subscriber? Click here to view full article